Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > VTYX Ventyx Biosciences > Detailed Quotes

VTYX Ventyx Biosciences

Watchlist
40.920
-1.540-3.63%
Close  02/08 16:00 ET
40.9200.0000.00%
Post Mkt Price 02/08 16:00 ET
High
42.590
Open
41.980
Turnover
23.14M
Low
40.620
Pre Close
42.460
Volume
562.95K
Market Cap
2.32B
P/E(TTM)
Loss
52wk High
44.980
Shares
56.64M
P/E(Static)
Loss
52wk Low
9.500
Float Cap
1.41B
Bid/Ask %
0.00%
Historical High
44.980
Shs Float
34.43M
Volume Ratio
0.89
Historical Low
9.500
Dividend TTM
--
Div Yield TTM
--
P/B
6.04
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.64%
Amplitude
4.64%
Avg Price
41.111
Lot Size
1
Float Cap
1.41B
Bid/Ask %
0.00%
Historical High
44.980
Shs Float
34.43M
Volume Ratio
0.89
Historical Low
9.500
Dividend TTM
--
P/B
6.04
Dividend LFY
--
Turnover Ratio
1.64%
Amplitude
4.64%
Avg Price
41.111
Lot Size
1
Price Forecast

News

Comment

Company Overview More
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in Encinitas, CA.
CEO: Dr. Raju S. Mohan, PhD
Market: NASDAQ
Listing Date: 10/21/2021
Paper Trade More
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist